1. 1) Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol., 2, 458–466 (2006).
2. 2) Okon T, Schwartzberg L. Are we winning the war on cancer? J. Oncol. Pract., 7 (Suppl.), 62s–64s (2011).
3. 3) Adjei AA, Budihardjo II, Rowinsky EK, Kottke TJ, Svingen PA, Buckwalter CA, Grochow LB, Donehower RC, Kaufmann SH. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: Inhibition of platinum–DNA adduct removal. Clin. Cancer Res., 3, 761–770 (1997).
4. 4) Wang W, Yang SM, Su Y, Xiao ZY, Wang CY, Li XF, Lin L, Fenton BM, Paoni SF, Ding I, Keng P, Okunieff P, Zhang L. Enhanced antitumor effect of combined triptolide and ionizing radiation. Clin. Cancer Res., 13, 4891–4899 (2007).
5. 5) Murata S, Adachi M, Kioi M, Torigoe S, Ijichi K, Hasegawa Y, Ogawa T, Bhayani MK, Lai SY, Mitsudo K, Tohnai I. Etodolac improves 5-FU sensitivity of head and neck cancer cells through inhibition of thymidylate synthase. Anticancer Res., 31, 2893–2898 (2011).